It has been demonstrated previously that HepG2 hepatoma cells are responsive to ActA: In these cells, treatment with exogenous rhActA leads to the phosphorylation of SMAD2, and this assay is thus suitable to measure the activity of ActA [26]. This evidence concerns the gene SMAD2 and hepatocellular carcinoma.